Shanghai OPM Biosciences Co. Ltd. A

OPM Biosciences released its half-year report, with both revenue and net profit rising sharply in the first half. Operating revenue reached 454 million yuan, up 155.24 percent year on year, while net profit attributable to the parent company was 124 million yuan, up 230.34 percent. The improvement was mainly driven by growth in the cell culture products business, whose revenue rose 34 percent year on year, while Pengli Biotech has been included in the consolidated statements since January this year, contributing 222 million yuan in revenue. OPM Biosciences also added a preclinical research CRO business this year, mainly because the company completed the acquisition and consolidation of Pengli Biotech in January. The preclinical drug CRO business achieved revenue of 182 million yuan, accounting for 40.11 percent of total revenue and becoming another major revenue pillar for the company. The company cautioned that price fluctuations in raw materials such as laboratory monkeys could have an adverse impact on operations.

Aopumai announced on August 30 that it plans to distribute a cash dividend of 2 yuan per 10 shares, before tax, to all shareholders, with an estimated total payout of 28.44 million yuan, accounting for 22.93% of net profit attributable to the parent company. In the first half of 2026, Aopumai achieved revenue of 454 million yuan and net profit attributable to the parent company of 124 million yuan.

Over the past week, STAR Market companies have been sending a flurry of positive signals. More than 30 companies announced new share buyback plans or progress updates, over 20 disclosed their 2026 half-year earnings forecasts with most reporting upbeat results, and several others signed major contracts or revealed R&D breakthroughs. The semiconductor supply chain is showing a cluster of strong performances. Puya Semiconductor expects first-half net profit attributable to the parent of about 825 million yuan, a more than 19-fold increase year-on-year. Dosilicon expects between 640 million and 680 million yuan, swinging from a loss to a profit. Yuanjie Technology expects net profit attributable to the parent of 600 million to 650 million yuan, up about 12-fold. Lianxun Instruments expects 510 million to 580 million yuan, up over 8-fold. Amlogic expects about 608 million yuan, up 22 percent. China Micro Semicon expects about 165 million yuan, up 91 percent, covering segments from memory and optical chips to SoCs. In biopharma, OPM Biosciences expects revenue of about 450 million yuan, up roughly 1.5 times, and net profit attributable to the parent of about 124 million yuan, up around 229 percent. In new energy and new materials, Minmetals New Energy and Oulai New Materials both expect to swing from losses to profits in net profit attributable to the parent. In the low-altitude economy, AVIC UAS expects revenue of 1.58 billion to 1.68 billion yuan, a more than 2.6-fold increase. On the buyback front, Montage Technology plans to repurchase 300 million to 600 million yuan worth of shares. Kingsoft Office has set a buyback cap of 500 million yuan and has already repurchased about 75 million yuan. Segway-Ninebot has cumulatively repurchased about 220 million yuan. Hoymiles Power Electronics' buyback ratio has exceeded 1 percent. Baimtec Material completed about 100 million yuan in buybacks using over-raised funds. Wasion Information completed 50 million yuan in buybacks. Controlling shareholders of Puya Semiconductor and Biwin Storage have proactively proposed buybacks. Market participants say the intensive buybacks and positive earnings forecasts reflect the growing quality of hard-tech companies and the accelerating release of industrial clustering effects.

Lianxun Instruments expects its net profit for the first half of 2026 to grow by 802% to 926% year-on-year, reaching 510 million to 580 million yuan, mainly driven by the development of artificial intelligence technology and rising global computing power demand, which has boosted demand for high-speed optical communication products. Biwin Storage chairman Sun Chengsi has proposed a share buyback of 200 million to 250 million yuan, with all repurchased shares to be cancelled to reduce registered capital. Sino Wealth Electronic estimates first-half net profit will rise 90.82% year-on-year to 165 million yuan, as the global AI and computing power boom spurs MCU demand. OPM Biosciences expects first-half net profit to increase 229% to around 124 million yuan, mainly due to the completion of its acquisition of Pengli Biotech. Ronbay Technology achieved a net profit of 109 million yuan in the first half, swinging from a loss a year earlier, with its lithium iron manganese phosphate products running at full production and sales. In other news, a subsidiary of Balance Medical received approval for China's first cross-linked collagen implant, ArcSoft's actual controller proposed an interim dividend of no less than 60% of first-half net profit, and Chaozhuo Aviation Technology's controlling shareholder is set to change to Taiyang Technology.

On July 15, the CRO sector led gains in the A-share market, with all stocks in the sector trading in positive territory. ChemPartner opened 1.04% higher in the morning session and quickly surged, eventually hitting the 20% daily limit up at 10.39 yuan per share, a gain of 19.98%. Joinn Laboratories and Baihua Pharmaceutical also hit their daily limit up, while Wanbang Pharmaceutical and OPM Biosciences rose more than 10%.